New injection shows promise for Tough-to-Treat skin cancer
NCT ID NCT07227870
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a new drug combination, L19IL2/L19TNF, injected directly into skin tumors. It is for people with advanced basal cell carcinoma that has worsened despite or cannot tolerate standard treatments. The study will enroll 92 participants and track how many respond to the therapy over up to 160 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
L19IL2/L19TNF (a combination of two immune-boosting proteins injected directly into tumors)
What this could lead to
If it works, this could offer a new treatment option for people with advanced basal cell skin cancer who have run out of other options.
What could go wrong
This is an early phase 2 trial with only 92 participants, so results may not apply to everyone. The treatment is injected directly into tumors, which may not be possible for all patients, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED BASAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc.
Tampa, Florida, 33612, United States
Contact
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Contact
-
Winship Cancer Institute, Emory University
Atlanta, Georgia, 30322, United States
Contact